Latest News - Pfizer
Top Corporates Hub
Pfizer
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q1
25.05.2026 19:23
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.
Pfizer's CEO uses AI to make his biggest calls — and 64% of CEOs agree, quietly shifting your portfolio
25.05.2026 11:00
More CEOs use AI to make business decisions than you might think.
Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38%
25.05.2026 10:05
As with other pharma companies, much rides on Pfizer's pipeline; it has many promising formulations in late-stage trials.
Pfizer Oncology Partnerships Add Detail To Valuation And Earnings Concerns
24.05.2026 02:08
Pfizer (NYSE:PFE) has entered a new alliance with Sarah Cannon Research Institute to accelerate oncology clinical trials and broaden patient access. The company has also granted Rigel Pharmaceuticals exclusive rights to commercialize VEPPANU, an FDA approved PROTAC based breast cancer therapy. These agreements reflect fresh moves in Pfizer's oncology R&D and commercialization approach that have not been covered in earlier updates. Pfizer's stock closed at $25.9, with the share price up 2.3%...
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
22.05.2026 13:00
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here’s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks
22.05.2026 12:40
Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued US Stocks According to Hedge Funds. On May 13, Pfizer Inc. (NYSE:PFE) announced receiving marketing authorization from the European Commission to expand the use of HYMPAVZI (marstacimab) for hemophilia A and B patients aged 12+ who have developed inhibitors. Management noted that roughly 20% of hemophilia […]
Pfizer: Reduced TrumpRx/Patent Risks Meet Accretive M&A Efforts - Reiterate Buy
22.05.2026 07:19
PFE's aggressive M&A and in-house R&D efforts are paying off, with the growth portfolio (newly launched/acquired products) already delivering $3.1B in...
Polycystic Kidney Disease Market Analysis Report 2026-2036, Profiles of Key Players - Otsuka Pharmaceutical, Novartis, Pfizer, and Vertex Pharmaceuticals
21.05.2026 13:20
The global polycystic kidney disease (PKD) market is expanding rapidly due to rising prevalence, advanced treatments, and increased awareness. The growing cases of chronic kidney diseases (CKD) including PKD, driven by factors like genetic mutations, hypertension, and diabetes, contribute to the market's growth. Innovations in diagnostics, such as MRI and genetic testing, facilitate early intervention in PKD cases. The approval of tolvaptan and ongoing research into therapies like lixivaptan off
The Most Undervalued Healthcare Stock in the S&P 500 Right Now
21.05.2026 11:25
The market appears to be short-sighted.
Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE)
21.05.2026 06:10
Earlier in May 2026, Pfizer reported positive Phase 2 results for its investigational 25‑valent pneumococcal conjugate vaccine in infants, showing strong immune responses versus PREVNAR 20 and prompting the launch of a pivotal Phase 3 pediatric program. The move to a broader 25‑strain infant vaccine candidate, alongside plans for a fifth‑generation 35‑valent adult vaccine, highlights how Pfizer is aiming to extend its long-standing pneumococcal franchise through higher‑value, next‑generation...
Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story
21.05.2026 05:12
Pfizer and its partners have granted Rigel Pharmaceuticals an exclusive license to commercialize VEPPANU (vepdegestrant), the first FDA approved oral PROTAC for advanced breast cancer. The agreement follows Phase 3 data that support clinical benefit in a difficult to treat patient group and inclusion of VEPPANU in NCCN breast cancer guidelines. The deal introduces a new commercialization pathway for VEPPANU and adds another partnership driven revenue channel for Pfizer. For investors...
Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer
20.05.2026 13:00
NASHVILLE, Tenn., May 20, 2026--Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, today announced a strategic collaboration with Pfizer Inc. to advance the development of Pfizer’s oncology portfolio through a science‑driven and scaled research program designed to bring promising therapies to patients faster and closer to home.
Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update
20.05.2026 10:43
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.
Pfizer Expands Pneumococcal Vaccine Push With New Programs
20.05.2026 09:14
Pfizer reports Phase 2 infant vaccine data showing a stronger immune response against serotype 3 versus Prevnar 20.
Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
20.05.2026 09:05
NEW YORK, May 20, 2026--Pfizer Inc. (NYSE: PFE) today announced data from its Phase 2 study (NCT06524414) evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent pneumococcal conjugate vaccine candidate PF-07872412 (25vPnC) in infants compared to four doses of PREVNAR 20 at months 2, 4, 6 and 12-15. Based on the strong immune responses observed for all 25vPnC serotypes from Phase 2, compared to PREVNAR 20, Pfizer is confident that the require
Pfizer Advances Next-Generation Pediatric Pneumococcal Vaccine After Phase 2 Data Showed Significantly Higher Serotype 3 Immune Response
20.05.2026 05:10
Phase 2 data demonstrate robust immunogenicity, including enhanced response against serotype 3, alongside expanded protection across 25 serotypes; to achieve potential vaccine serotype coverage of 90% in the pediatric
[Latest] Global Cholera Vaccine Market Size/Share Worth USD 649 Million by 2035 at a 7.6 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
19.05.2026 04:30
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Cholera Vaccine Market size & share revenue was valued at approximately USD 312 Million in 2025 and is expected to reach USD 336 Million in 2026 and is expected to reach around USD 649 Million by 2035, at a CAGR of 7.6 between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Sanofi S.A., Hilleman Laboratories, Bi
Wolfe Research Says COVID Uncertainty Continues to Weigh on Pfizer (PFE) Outlook
16.05.2026 10:56
With an annual dividend yield of 6.68%, Pfizer Inc. (NYSE:PFE) is included among the 10 Best Dividend Stocks with 5%+ Yields and Growing Cash Flows. On May 14, Wolfe Research analyst Alexandria Hammond raised the firm’s price recommendation on Pfizer Inc. (NYSE:PFE) to $26 from $25. It reiterated an Underperform rating on the shares following what the […]
Pfizer Hemophilia Approval Expands HYMPAVZI Reach And Supports Valuation Case
16.05.2026 00:21
Pfizer (NYSE:PFE) received European Commission approval to expand HYMPAVZI to adolescents with hemophilia A or B and inhibitors. The decision opens access to a new patient group within the EU hemophilia market for this rare disease therapy. The expanded label highlights bleed protection and a simplified administration regimen for a hard to treat population. For investors watching NYSE:PFE, this update is part of Pfizer's broader push in rare diseases, an area where specialized treatments...
5 Must-Read Analyst Questions From Pfizer’s Q1 Earnings Call
15.05.2026 08:52
Pfizer’s first quarter results reflected continued momentum in its core portfolio, with management attributing growth to strong performance in recently launched and acquired products, particularly in oncology and migraine therapies. CEO Albert Bourla credited a 22% increase in revenues from new products and acquisitions, highlighting the success of the Seagen integration and robust demand for Nurtec. Management also pointed to positive developments in legal settlements, which have improved clari